Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia

被引:34
|
作者
Sakabe, K [1 ]
Fukuda, N [1 ]
Wakayama, K [1 ]
Nada, T [1 ]
Shinohara, H [1 ]
Tamura, Y [1 ]
机构
[1] Natl Zentsuji Hosp, Dept Cardiol & Clin Res, Kagawa 7658507, Japan
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 04期
关键词
D O I
10.1016/j.amjcard.2004.04.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this prospective study, we found beneficial short-term effects from atorvastatin therapy, including effects on low-density lipoprotein subfractions and remnant-like lipoprotein particle cholesterol, antioxidant effects, and alterations in endothelial function that may be important in early benefit from statin therapy; some effects would support much earlier benefit than previously reported. We also found long-term effects of atorvastatin, including decreased plasminogen activator inhibitor type-1 and additional significant alterations in low-density lipoprotein subfractions and endothelial function, supporting benefits from continuous long-term atorvastatin therapy beyond early reversal of hypercholesterolemia. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:497 / 500
页数:4
相关论文
共 50 条
  • [1] Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study)
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Grundy, Scott M.
    Hsueh, Willa A.
    Parving, Hans-Henrik
    Rosen, Jeffrey B.
    Adewale, Adeniyi J.
    Polis, Adam B.
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (12): : 1694 - 1702
  • [2] Hepatotoxic Effects of Lipid-Altering Agents
    Korth, Christine E.
    Backes, James M.
    US PHARMACIST, 2012, 37 (09) : HS17 - HS20
  • [3] Lipid-altering efficacy and safety of ezetimibe/simvastatin versus rosuvastatin in patients with primary hypercholesterolemia
    Davidson, M. H.
    Catapano, A. L.
    Ballantyne, C. M.
    Brady, W. E.
    Gazzara, R. A.
    Tershakovec, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 555 - 555
  • [4] Lipid-altering effects of different formulations of hydroxypropylmethylcellulose
    Maki, Kevin C.
    Carson, Michael L.
    Anderson, W. H. Kerr
    Geohas, Jeffrey
    Reeves, Matthew S.
    Farmer, Mildred V.
    Turowski, Maciej
    Miller, Marvin
    Kaden, Valerie N.
    Dicklin, Mary R.
    Rains, Tia M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2009, 3 (03) : 159 - 166
  • [5] Lipid and pleiotropic effects of atorvastatin in patients with high cardiovascular risk
    Karpov, R. S.
    Koshelskaya, O. A.
    Sushkova, A. S.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2009, 8 (08): : 30 - 35
  • [6] Lipid and pleiotropic effects of atorvastatin in patients with acute coronary syndrome
    Yalymov, A. A.
    Shekhyan, G. G.
    Bylyeva, A. A.
    Zadionchenko, V. S.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2009, 8 (07): : 64 - 72
  • [7] Lipid-altering agents: the future
    Wierzbicki, AS
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (11) : 1063 - 1072
  • [8] WHICH PATIENTS NEED AGGRESSIVE LIPID-ALTERING THERAPY
    HUNNINGHAKE, DB
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 1993, 60 (06) : 483 - 484
  • [9] Lipid attainment among patients newly treated with lipid-altering drugs
    Hess, Gregory
    Chang, Chun-Lan
    Chung, Karen
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (09) : 1743 - 1756
  • [10] Lipid-altering efficacy and tolerability profile of extended release niacin/laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia
    Maccubbin, D.
    Sirah, W.
    Betteridge, A.
    Yu, Q.
    Sisk, C. Mccrary
    Bays, H.
    Olsson, A. G.
    Paolini, J.
    EUROPEAN HEART JOURNAL, 2007, 28 : 108 - 108